Polymeropoulos Mihael Hristos's Form 4 filing
Vanda Pharmaceuticals Inc. (VNDA) · filed Dec 2, 2021
- Accession no.
- 0001209191-21-067592
- Filed
- Dec 2, 2021
- Trade date
- Nov 30-Dec 1, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.56M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Polymeropoulos Mihael HristosCIK 0001355537 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 30, 2021 | Common Stock | MOption exerciseAcquired | +78,324 | $4.88 | +$382,221.12 | 1,299,386 | Direct | |
| Nov 30, 2021 | Common Stock | SSaleDisposed | −50,000 | $16.49 | −$824,500 | 1,249,386 | Direct | |
| Dec 1, 2021 | Common Stock | MOption exerciseAcquired | +71,676 | $4.88 | +$349,778.88 | 1,321,062 | Direct | |
| Dec 1, 2021 | Common Stock | SSaleDisposed | −46,200 | $16.00 | −$739,200 | 1,274,862 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 30, 2021 | Common Stock | MOption exerciseDisposed | −78,324 | $0.00 | $0 | 71,676 | Direct | |
| Dec 1, 2021 | Common Stock | MOption exerciseDisposed | −71,676 | $0.00 | $0 | 0 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.